StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ARWRBullishIndustry Newsnews
High materiality9/10

Arrowhead delivers strong SHASTA data; advances sHTG regulatory path

Jul 22, 2026, 7:36 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strength of Phase 3 data (large TG reductions, substantial AP risk reduction, favorable safety) plus imminent regulatory milestones (U.S. sNDA by end-2026 and ESC event) suggest a positive re-rating for ARWR, barring unforeseen safety or competitive developments.

AI summary

What happened, with direct paths to the underlying reporting

Arrowhead reported topline Phase 3 results for plozasiran in severe hypertriglyceridemia, showing deep triglyceride reductions and fewer acute pancreatitis events with favorable safety. TG reductions reached 79% and 81% at 12 months, while pancreatitis events declined 78% overall and 100% in the highest-risk group. The company plans a U.S. sNDA by year-end 2026 with ESC data presentation on August 30, 2026, signaling a clear regulatory and commercial pathway ahead.

  • SHASTA-3/SHASTA-4: TG reductions of 79% and 81% at 12 months.
  • AP events reduced 78% across sHTG; 100% in high-risk subgroup.
  • Safety profile remains favorable; no new safety signals.
  • US sNDA for plozasiran planned before year-end 2026; ESC presentation Aug 30, 2026.
  • Sanofi China rights to REDEMPLO; Arrowhead retains global rights elsewhere.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event